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Abstract: Considering the importance of ultra-performance liquid chromatography-electrospray
ionization-quadrupole time of flight-tandem mass spectrometry (UPLC-ESI-QTOF-MS/MS)
hyphenated techniques for analysis of secondary metabolites from crude extracts, the present
study was aimed at identification of secondary metabolites in acetone extract of the lichen
Usnea longissima. From our study, 19 compounds were tentatively identified through comparison
of exact molecular masses from their MS/MS spectra, mass fragmentation studies and comparison
with literature data. In addition, potent cytotoxic activity of U. longissima extract prompted us to
isolate four compounds, 18R-hydroxy-dihydroalloprotolichesterinic acid (19), neuropogolic acid (20),
barbatic acid (21), and usnic acid (22) from this extract which were adequately identified through
mass spectrometry and NMR spectroscopy. All four compounds displayed cytotoxic activity. Barbatic
acid (21) manifested doxorubicin equivalent activity against A549 lung cancer cell line with IC50
of 1.78 µM and strong G0/G1 accumulation of cells. Poly ADP-ribose polymerase (PARP) cleavage
confirmed that it induced cytotoxic activity via apoptosis. Finally, our work has discerned the depside,
barbatic acid (21) from crude extract as a candidate anti-cancer molecule, which induces cell death by
stepping up apoptosis.
Keywords: lichen; U. longissima; parmeliaceae; UPLC-ESI-QTOF-MS/MS; cytotoxic activity;
cell cycle studies
Molecules 2019, 24, 2270; doi:10.3390/molecules24122270 www.mdpi.com/journal/molecules
Molecules 2019, 24, 2270 2 of 19
1. Introduction
Lichens are fungi (mostly Ascomycetes) that feed on populations of microscopic algae/cyanobacteria
in the framework of a symbiotic type of relationship. Apart from their ecological importance, they
have become important natural medicinal resources due to the production of a large number of unique
secondary metabolites (depsides, depsidones, dibenzofurans, pulvinic acid derivatives) and pigments
(anthraquinones, napthoquinones, and xanthones) which can act as biomarkers as well as bioactive
compounds [1–4]. Usnea longissima Ach. is a hanging hair lichen, that grows circumpolar in high humidity
inland areas and coastal forests of Europe, Asia, and North America [5]. This lichen has been used
therapeutically for centuries in Indian traditional systems of medicine for its analgesic, cardiotonic,
stomachic, and wound healing properties [6]. Its crude extracts are consumed by tribal communities
to treat fevers and bone fractures [7]. Previous studies on its chemical constituents have resulted in
isolation of several bioactive secondary metabolites which include monosubstituted phenyls, depsides,
anthraquinones, dibenzofuran derivatives, and terpenoids [8–10]. However, chemical variations are
illustrated by the report of seven chemical strains found in the Uttarakhand region, India: (i) barbatic
acid and usnic acid (ii) squamatic acid, barbatic acid and usnic acid (iii) diffractaic acid and usnic acid (iv)
evernic acid and usnic acid (v) fumarprotocetraric acid and usnic acid (vi) squamatic acid and usnic acid
and (vii) usnic acid only [11]. Mallavadhani et al. also reported this species as new source (−)-placodiolic
acid along with barbatic acid, ergosterol-5β, 8β-peroxide and (+)-usnic acid from a sample collected
in Sikkim, India [12]. Similarly, chemical variations of U. longissima are described within the central
Coast Range of Oregon [5] as in Southern Far East Russia and in Japan [13]. Most of these depsides
and dibenzofuran derivatives (especially usnic acid) are supposed to be responsible for their multiple
pharmacological activities [9] and some of its major compounds were absorbed in blood of animals fed
with this lichen [14].
As part of our continuous endeavors of phytochemical–pharmacological integrated studies on
Indian lichens for bio-actives [15], a biological screening is developed in parallel to an Ultra Performance
Liquid Chromatography-Photo Diode Array-high-resolution Time of Flight Mass Spectrometric
(UPLC-PDA-ESI-Q-TOF-MS/MS) method for comprehensive analysis of secondary metabolites in
crude acetone extract (Figure 1). Using this analytical technique, 23 secondary metabolites (Figure 2)
were characterized from the crude acetone extract through their accurate molecular masses, molecular
formula, and comparison of the literature database (DNP) which revealed the presence of unreferenced
compounds. Initial screening of the acetone extract of the fruticose lichen U. longissima was carried out
against cancer cell lines, HeLa (cervical), A549 (lung), MCF-7 (breast), DU-145 (prostate) and HEK-293,
a Human embryonic kidney cell line. Interestingly, it was found that the crude extract displayed
potent cytotoxic activity, particularly against A-549 cell line. Subsequent bio-guided phytochemical
investigation led to the isolation and identification of four compounds (19–22) (Figure 3). The structures
of these compounds (19–22) were elucidated on the basis of extensive spectroscopic techniques,
especially NMR and mass spectrometry data. Single X-ray crystal structure of barbatic acid (21) was
given for the first time in this study. The aim of our study described here was to identify metabolites
responsible for bioactivity of lichen and to explicate their mechanism of action. Therefore, isolates
(19–22) were appraised for cytotoxicity against cancer cell lines.
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2. Results and Discussion
2.1. Isolation of Major Compounds from Acetone Extract of U. longissima
and UPLC/PDA/ESI-QTOF-MS Analysis
Concentrated acetone extract was chromatographed on silica gel and resultant fractions were subjected
to bioassay for cytotoxic activity against cancer cell lines. Repeated column chromatography of bioactive
fractions resulted in the isolation of four compounds. Comparing their physical and spectroscopic data with
literature, they were characterized as 18R-hydroxy-dihydroalloprotolichesterinic acid (19) [16], neuropogolic
acid (20) [17], barbatic acid (21) [18], and (+)-usnic acid (22) (Figure 3) [19]. The structure of barbatic
acid (21) was further confirmed by single crystal X-ray diffraction analysis (Figure 4). To the best of our
knowledge, this is the first report of crystal structure of barbatic acid (21).
Molecules 2019, 24, x FOR PEER REVIEW 5 of 18 
 
2. Results and Discussion 
2.1. Isolation of Major Compounds from Acetone Extract of U. longissima and UPLC/PDA/ESI-QTOF-MS 
Analysis  
Concentrated acetone extract was chromatographed on silica gel and resultant fractions were 
subjected to bioassay for cytotoxic activity against cancer cell lines. Repeated column 
chromatography of bioactive fractions resulted in the isolation of four compounds. Comparing their 
physical and spectroscopic data with literature, they were characterized as 18R-hydroxy-
dihydroalloprotolichesterinic acid (19) [16], neuropogolic acid (20) [17], barbatic acid (21) [18], and 
(+)-usnic acid (22) (Figure 3) [19]. The structure of barbatic acid (21) was further confirmed by single 
crystal X-ray diffraction analysis (Figure 4). To the best of our knowledge, this is the first report of 
crystal structure of barbatic acid (21). 
 
Figure 4. Crystal structure of barbatic acid (21): the molecular structure of barbatic acid, with the 
atom-numbering scheme. Displacement ellipsoids are drawn at the 30% probability level and H atoms 
are shown as small spheres of arbitrary radius. Intramolecular hydrogen bonds are shown as dashed 
lines. 
Recently, Salgado et al. [20] reported finger printing analysis of secondary metabolites from four 
Usnea species (U. barbata, U. antarctica, U. rubicunda, and U. subfloridana), using hyphenated 
techniques. Concerning U. longissima, most of the qualitative and quantitative analysis were limited 
to HPLC or HPTLC studies based on their UV data and retention times. Therefore, in continuation of 
previous studies on fragmentation patterns on natural products [21] we investigated the crude extract 
of U. longissima via reverse phase UPLC/PDA/ESI-QTOF-MS, using a gradient mobile phase 
consisting of acetonitrile and water containing 0.1% formic acid that allowed for a comprehensive 
elution of the analyte within 16 min. Based on these optimized conditions, acquired total ion current 
chromatograms (TIC) were analyzed in ESI negative ionization mode and these results are presented 
in Table S1 and Figure 2. Metabolite assignments were made based on their MS spectral data (accurate 
mass and fragmentation pattern), retention times, comparison to the standard compounds (in-house 
library), and search in public online-databases (DNP, Reaxys and SciFinder), respectively [22]. This 
study led to the identification of 23 metabolites distributed in lipids, depsides, depsidones, paraconic 
acids, and dibenzofuran classes (Figure 2).  
2.2.  Structural Fragmentation Analysis 
All the metabolites were classified based on their common fragmentation ions in MS/MS spectra. 
Consideration of their UV absorption in PDA and high-resolution masses allowed dereplication of 
the reference compounds as well as putative characterization of certain secondary metabolites for the 
first time in the extract. Results are shown in Table S1. Initial TOF-MS/MS scan of the depsidone 
derivative, salazinic acid (1) showed [M − H]− ions at m/z 387.0346. Subsequently, ESI-CID-MS/MS 
analysis of 1 indicated a high abundant product ion [M – H-44]− at m/z 343.0455, formed due to loss 
Figure 4. Crystal s ructure of barbatic acid (21): the molecula structure of barbat c acid,
with the atom-numbering cheme. Displacement llipsoids are drawn at the 30% probability level
and H atoms are shown as sm ll spheres of arbitra y radius. Intramolecular hydrogen bonds are shown
as dashed lines.
Recently, Salgado et al. [20] reported finger printing analysis of secondary metabolites from
four Usnea species (U. barbata, U. antarctica, U. rubicunda, and U. subfloridana), using hyphenated
techniques. Concerning U. longissima, most of the qualitative and quantitative analysis were limited
to HPLC or HPTLC studies based on their UV data and retention times. Therefore, in continuation
of previous studies on fragmentation patterns on natural products [21] we investigated the crude
extract of U. longissima via reverse phase UPLC/PDA/ESI-QTOF-MS, using a gradient mobile phase
consisting of acetonitrile and water containing 0.1% formic acid that allowed for a comprehensive
elution of the analyte within 16 min. Based on these optimized conditions, acquired total ion current
chromatogra s (TIC) ere analyzed in ESI negative ionization ode and these results are presented in
Table S1 and Figure 2. Metabolite assignments were made based on their MS spectral data (accurate mass
and fragmentation pattern), retention times, comparison to the standard compounds (in-house library),
and search in public online-databases (DNP, Reaxys and SciFinder), respectively [22]. This study led
to the identification of 23 metabolites distributed in lipids, depsides, depsidones, paraconic acids,
and dibenzofuran classes (Figure 2).
2.2. Structural Fragmentation Analysis
All the metabolites were classified based on their common fragmentation ions in MS/MS spectra.
Consideration of their UV absorption in PDA and high-resolution masses allowed dereplication
of the reference compounds as well as putative characterization of certain secondary metabolites
for the first time in the extract. Results are shown in Table S1. Initial TOF-MS/MS scan of the depsidone
derivative, salazinic acid (1) showed [M − H]− ions at m/z 387.0346. Subsequently, ESI-CID-MS/MS
analysis of 1 indicated a high abundant product ion [M – H-44]− at m/z 343.0455, formed due to loss of
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CO2 which is in line with fragmentation pattern of depsidones [23]. Further, it also showed a fragment
ion at m/z 313.0346 by loss of CH2O, and at m/z 269.0451 by loss of CO2, respectively confirming
the structure of 1 as salazinic acid (Supplementary Figure S5). Similarly, based on MS/MS spectra,
compounds 2, 3, 4, 5, 7, 8, 10, 11, and 13 were tentatively identified as lipids i.e., polyhydroxy fatty
acids, tri-hydroxyfatty acid (2), tetra-hydroxy fatty acids (3, 4, 5, and 10), and hexa-hydroxy fatty acids
(7, 8, 11 and 13). For explanation of fragmentation pattern, compound 3 was taken as a representative.
Its TOF-MS/MS spectra was analyzed, which showed [M −H]− ion at m/z 375.2742 (C20H39O6) with
key fragment ions 245.1393, 217.1447, 141.0916, and 127.1121 formed by cleavage of C-C bonds (C8-C9,
C11-C12, C12-C13) adjacent to hydroxyl groups. The remaining hydroxy fatty acids also followed similar
fragmentation pattern along with loss of H2O molecules as shown in the Supplementary Material.
Further, it was observed that four polyhydroxy fatty acids (2, 3, 5, 10) are being reported for the first
time in this species.
ESI-QTOF-MS scan (negative mode) of dibenzofuran related compounds including usnic acid (22),
usenamine A (14) [8], and compounds 24 and 25 showed [M − H]− ion peaks at m/z 343.0822 (22),
342.0977 (14), 357.0974 (24), and 412.1766 (25) respectively. Usnic acid (22) MS/MS spectrum showed
a deprotonated ion [M − H]− at m/z 343.0822 and an odd electron ion at m/z 328, corresponding to
[M − H-CH3]− [24]. Further, a diagnostic fragment at m/z 259 is proposed to be generated from
molecular ion m/z 343 through Retro Diels Alder (RDA) cleavage of ring C. Fragment at m/z 231
was due to the loss of CO from m/z 259. Compounds 24 and 25 were similar to that of 22 and 14
respectively, except for the presence of methoxy group in 24 and n-pentyl side chain at NH2 in 25.
The characteristic RDA feature of ring C, resulted in product ions at m/z 259.0607 and m/z 152.1072
with high abundance in MS/MS spectrum of 25, and fragment ions at m/z 97.0284, 259.0604 in MS/MS
spectrum of 24. Thus, based on their MS/MS fragmentation studies (Figure 5), structures of 24 and 25
were tentatively identified. These compounds were not reported in a recent phytochemical study on
usnic acid derivatives while additional usenamines, usone, and isousone were isolated and identified
from large quantities of U. longissima collected in the Sichuan province [8].
Compound 6 is a simple phenolic compound in nature (Supplementary Figure S10) whereas
compounds 12 and 21 were depsides, as concluded by fragmentation (Supplementary Figures S16
and S25). Compounds 15, 17, 18, 19, 20, and 23 belong to the class of paraconic acid/aliphatic acid-type
compounds [20,25] with similar fragmentation pathways and profiles of product ions. Compound 15
was taken for explanation. TOF-MS/MS spectrum indicated the product ions at m/z 339.2534, 295.2635,
and 253.2164 were formed from molecular ions by sequential CO2 loss and aliphatic chain breakage.
Loss of hydroxyl-, keto-group and side chains were also observed in some of the compounds.
In the present study, a depsidone, salazinic acid (1) which is well reported in Usnea genus but rarely
in U. longissima is a marker of this chemotype [26]. Gagarina et al. have recorded three chemotypes in
Yakutia (Russia): (i) medulla with salazinic acid, cortex with usnic acid; (ii) medulla with salazinic,
barbatic acid, fatty acids, cortex with usnic acid; (iii) medulla with salazinic, evernic, diffractaic acids,
cortex with usnic acid [27]. Based on our HPTLC (Supplementary Figure S3), UPLC-PDA-TOF-MSe
(Supplementary Figure S4) and isolation we found usnic acid, barbatic acid, salazinic acid and fatty
acids in our sample, which clearly matches with chemotype-2 reported by these authors.
Among 23 compounds identified by MS/MS, five homologous polyhydroxy fatty acids (4, 7, 8, 11,
13), two paraconic acids (15, 18), and two dibenzofuran related metabolites (24 and 25) were identified
for the first time. Fragmentation pathways (Supplementary Figures S5–S30), molecular formulas,
and HR-MS/MS parameters (Supplementary Table S1) are presented in the Supplementary Material
and structures are shown in Figure 2.
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2.3. Biological Activity
Initially, crude acetone extract was screened against a panel of human cancer cell lines,
HeLa (cervical), A-549 (lu g), MCF-7 (breast), DU-145 (prostate), HEK-293 and a Human embryonic
kidney cell line, highlighting a potent inhibitory activity against A549 cell line. Fou compou ds
(19–22) were isolated from the crude acetone extract of Usnea long ssima based on a bioassay-guided
fractionati n and wer gain t sted for their cytotoxicity ag inst those cell lines by MTT assay [28].
The clinically applied anticancer agent, doxorubicin, was used as positive control for cytotoxicity assa .
As shown in Tabl 1, barbatic acid (21) manifeste potent activity against A549 cell line with IC50 value
of 1.78 ± 0.62 µM, which is almost equivalen to the stand rd drug, doxorubicin. However, cytot xicity
value against norm cell line (HEK-293) wa found >100 µM. Inhi tory activity of barbat acid (21)
on A549 and DU-145 cell lines is comparable to the previously rep rted activities agains MCF-7 (breast
cancer) [29] and HeLa (cerv x arcinoma) [30] c ll lines. This pr nounced activity of barbatic acid (21)
prompted us to investigate ts effect on the cell cycle by flow cytometry.
Molecules 2019, 24, 2270 8 of 19
Table 1. IC50 values for acetone extract and isolated compounds 19–22 on selected human cell lines.
HeLa a A549 b MCF-7 c DU-145 d HEK-293 e
Crude extract 25.33 ± 1.23 9.11 ± 2.76 14.67 ± 2.85 20.88 ± 3.74 78.33 ± 2.11
19 22.67 ± 0.97 20.20 ± 1.99 20.01 ± 0.74 26.97 ± 2.92 55.87 ± 1.55
20 23.63 ± 0.74 19.13 ± 3.86 22.30 ± 4.05 26.10 ± 1.09 112.77 ± 3.82
21 3.02 ± 0.11 1.78 ± 0.62 3.16 ± 0.88 9.03 ± 2.11 124.90 ± 2.65
22 18.88 ± 2.06 13.80 ± 1.11 19.18 ± 2.05 24.21 ± 0.99 125.20 ± 1.98
Doxorubicin 1.55 ± 1.32 1.95 ± 0.97 1.62 ± 0.36 1.51 ± 0.84 NT
50% cell proliferation inhibitory concentration (IC50) after 48 h of compound treatment. IC50 values presented
for extract is in µg/mL and for compounds in µM. a Human cervical cancer, b Human lung cancer, c Human breast
cancer, d Human prostate cancer and e Normal cell lines. NT: Not tested [31].
2.3.1. Cell Cycle Analysis
The screening results revealed that barbatic acid (21) showed significant anticancer activity against
human lung cancer cell line, A549. To understand whether this cell growth inhibition of A549 cells was
due to cell cycle arrest, we performed a cell cycle analysis study. In this study, A549 cells were treated
with barbatic acid (21) for 24 h at 1 and 2 µM concentrations. The data obtained clearly indicated that
this compound showed cell cycle arrest in G0/G1 phase with 70.9% and 74.4% of cell accumulation in
G0/G1 phase at 1 and 2 µM concentration, respectively (Figure 6).
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Figure 6. Flow cytometric analysis in A549 cells. (A) Control cells and cells treated with Doxorubicin
(2 µM) and barbatic acid (21) at 1 and 2 µM concentrations. (B) Bar chart showing the cell cycle phase
distribution of A549 cells. Values are mean ± SE, n = 3. Tukey’s multiple comparison test followed
by ANOVA was applied to compare the differences. # p < 0.001 (control vs. 21 at 1 µM), * p < 0.0001
(control vs. 21 at 2 µM).
2.3.2. Hoechst Staining for Apoptosis
To validate whether barbatic acid (21) indeed caused apoptosis in A549 cells, we analyzed
the nuclear fragmentation in treated cells, as one of the characteristics of apoptosis includes chromatin
condensation and fragmentation of nuclei in inducing programmed cell death [32]. To achieve this,
we treated A549 cells with 1 and 2 µM concentrations of barbatic acid for 48 h. Microscopic examination
of Hoechst stained cells revealed chromatin condensation and fragmented nuclei indicating induction
of apoptosis in A549 cells due to compound treatment (Figure 7).
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Doxorubicin (2 µM) and barbatic acid (21) at 1 and 2 µM concentrations. Florescence images were
captured by Olympus microscope using 10X lens.
2.3.3. Annexin V Staining
Since our flow cytometry and nuclear stain analysis revealed that barbatic acid causes cell death,
we corroborated our observation with Annexin V st ining. W chose to pe form Annexin V staining as,
Phosphatidyl serine (PS), a lipid normally confined to the inner leaflet of the plasma membr ne, is
exported to the out plasma membrane le flet during ap ptosis to serve as a trigger for recognition of
apopt tic cells by phagocytes [33]. Therefore, to el cidate this, A549 cells were treated with barbatic
acid (21) for 24 h at 1 and 2 µM concentrations. It was observe that compound 21 induced apoptosis by
externalizing phosphatidyl serine as evidenced by robust annexin V staining (Figure 8). Furthermore,
our results indicated that when compared to control (1.12%), barbatic acid (21) showed at about 7.78%
and 9.29% total apoptosis at 1 nd 2 µM concentrations, respec ively (Figure 8).
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2.3.4. Immunoblot Assay for Poly (ADP-ribose) polymerase (PARP)
Poly (ADP-ribo e) p lymerase ( ARP) cleavage h been ascribed as one of the hallmarks of
apoptosis [34]. Immunoblot analysis revealed that 21 led to robust cleavage of PARP protein similar
to doxorubicin treatments (Figure 9). In addition, we analyzed for CDK4 and Cyclin D1 protein
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levels, as they promote the transition of cell cycle from G1 to S. CDK4 and Cyclin D1 protein levels
accumulated in compound 21 and doxorubicin treated cells (Figure 9).
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2.3.5. Caspase-3 Assay
To further confirm that compound 21 indeed causes cell death, we sought to determine intracellular
activities of caspase-3. To achieve this, we treated A549 cells with 1 and 2 µM concentrations of 21 with
doxorubicin as a positive control and performed fluorimetric assays. As expected, caspase-3 activity
increased maximally in 2 µM of 21 treated cells. Whereas, untreated or vehicle treated cells did not
show any activation in caspase-3 levels (Figure 10).
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Figure 10. Caspase-3 assay of barbatic acid (21). A549 cells were seeded and treated with 1 and 2 µM
of 21. Subsequently, the cells were harvested, and lysates were subjected to cellular caspase 3 analysis.
As a positive control doxorubicin was employed. UT represents untreated cells and D is DMSO, vehicle
control. Values are mean ± SD, the assay was repeated two times in triplicates (n = 6). * p < 0.05 vs.
control is treated as statistically significant.
Molecules 2019, 24, 2270 13 of 19
Thus, we could show that barbatic acid (21) is a potent cytotoxic agent which causes apoptosis
through accumulation of cells in G0/G1, activation of caspase-3 that correlates with appearance of
cleaved PARP protein.
3. Materials and Methods
3.1. Lichen Sample
U. longissima (Common name: Old Man’s beard) was collected in the month of November 2013
from Osla region between altitude range 3000–3500 and Hari-ki-dun region between altitude range
3500–4000 m in Uttarkashi district of Uttarakhand state of India [11,35]. Specimens were recorded with
accession no. 28,382 (lichen from Osla), and no. 12-018850 (lichen from Hari-ki-dun) and deposited in
the CSIR-National Botanical Research Institute (Lucknow, India) Herbarium. The lichen was authenticated
by Prof. D. K. Upreti, and a dissecting microscope was used for identification of morphological
characteristics of the thallus, reproductive structures, color, size and shape. Spot test reactions were
performed on the thallus under the dissecting microscopy. Spot test by para-phenylenediamine (P),
potassium hydroxide (K), sodium hypochlorite (C) or/and KC reagent characters and comparison to
the standard literature [27,36] were referred for identification of lichen samples (Supplementary Figure S2).
Three major lichen substances were visualized with high performance thin layer chromatography in
toluene/Dioxan/Acetic acid—72.50:24.19:3.22 solvent system (Supplementary Figure S3).
3.2. Chemicals and Reagents
HPLC-grade acetonitrile was obtained from Biosolve Chimie SARL (Dieuze, France), formic acid
(Optima LC/MS grade) from Fisher Scientific (Geel, Belgium), and methanol (LiChrosolv) was purchased
from Merck (Darmstadt, Germany). Ultra-pure water (Milli-Q, Millipore, Milford, MA, USA) was used
throughout the study.
3.3. Extraction and Purification of Constituents from U. longissima
The lichen U. longissima (300 g) was shade dried, powdered and extracted with acetone at room
temperature for 48 h. Resulting acetone extract was evaporated to dryness under reduced pressure
affording syrupy residue (13 g). Crude extract was subjected to gradient column chromatography
(silica gel, 100–200 mesh, eluting with hexane/EtOAc mixtures of increasing polarity) to give four
major fractions (F1–F4). Repeated purifications of fraction F1 on silica gel (100–200 mesh) with
elution of hexane:EtOAc (60:40 v/v) yielded (+) usnic acid (22) (1.5 g) [8,19] in pure form. Similarly,
purification of fraction F2 was achieved by flash chromatography with elution of hexane:EtOAc
(50:50 v/v) followed by recrystallization to yield barbatic acid (21) (30 mg) [18]. Repetitive purification
of fraction F3 on silica gel (100–200 mesh and 230–400 mesh) on elution with hexane:EtOAc (50:50 v/v)
yielded 18R-hydroxy-dihydroalloprotolichesterinic acid (19) (25 mg) [16]. Fraction F4 was then purified
on silica gel (100–200 mesh) and elution with hexane:EtOAc (50:50 v/v) yielded neuropogolic acid (20)
(5 mg) [17].
3.4. Spectral Data
18R-hydroxy-dihydroalloprotolichesterinic acid (19): White solid; [α]D25 −8.00 (c = 0.1, CHCl3);
1H-NMR (700 MHz in Acetone D6) δ 2.95 (1H, m, H-2), 3.29 (1H, dd, J = 8.9, 8.3, H-3), 4.70 (1H, ddd,
J = 8.0, 8.5, 5.8, H-4), 1.28 (2H, m, H-6), 1.28 to 1.24 (18H, m, H-7 to 15), 1.28 (2H, m, H-16), 1.59 (2H,
m, H-17), 3.67 (1H, m, H-18), 1.10 (3H, d, J = 6.1, H-19), 1.22 (3H, d, J = 7.1, H-20); 13C-NMR (175
MHz in Acetone D6) δ 177.1 (C-1), 36.4 (C-2), 51.1 (C-3), 77.2 (C- 4), 30.9 (C-5), 25.65 (C-6), 29.0- 28.0
(C-7 to 15), 25.6 (C-16), 39.4 (C-17), 66.6 (C-18), 23.1 (C-19), 13.7 (C- 20), 174.3 (C-21); ESI-MS m/z 369
[M − H]−.
Neuropogolic acid (20): White solid; [α]D25 +20.6 (c = 0.09, CHCl3); 1H-NMR (700 MHz in
CDCl3 + CD3OD) δ 5.15 (1H, m, H-4), 1.45 to 1.62 (22H, m, H-7 to 17), 3.72(1H, m, H-18), 1.15 (3H, d,
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J = 6.1, H-19), 2.16 (3H, d, J = 2.0, H-20); 13C-NMR (75 MHz in CDCl3 + CD3OD) δ 172.3 (C-1), 139.0
(C-2), 146.6 (C-3), 81.0 (C-4), 32.2 (C-5), 24.2 (C-6), 29.1- 28.8 (C-7 to 15), 23.4 (C-16), 43.4 (C-17), 66.5
(C-18), 29.1 (C-19), 10.5 (C-20), 165.1(C-21) ; ESI-MS m/z 391 [M + Na]+.
Barbatic acid (21): White crystal; 1H NMR (500 MHz in DMSO-D6) δ 10.73 (1H, s, 2′-OH), 3.86
(3H, s, 4- OMe), 6.59 (IH, s, H-5), 6.68 (1H, s, H-5′), 1.99 (3H, s, H-8), 2.00 (3H, s, H-8′), 2.48(3H, s,
H-9), 2.56 (3H, s, H-9′). 13C-NMR (100 MHz in DMSO-D6) δ 106.2 (C-1), 161.0 (C-2), 109.9 (C-3), 161.2
(C-4), 55.6 (4-OCH3), 106.9 (C-5), 138.9 (C-6), 168.5 (C-7), 9.0 (C-8), 23.0 (C-9), 115.6 (C-1′), 159.4
(C-2′), 111.34 (C-3′), 151.7 (C-4′), 115.9 (C-5′), 138.9 (C-6′), 173.0 (C-7′), 7.9 (C-8′), 22.7 (C-9′).; ESI-MS
m/z 359 [M − H]−.
Usnic acid (22): Yellow solid; [α]D25 + 163.9 (c = 0.05, CHCl3); 1H-NMR (500 MHz in CDCl3): δ
5.98 (H-4), 13.31 (1H, s, 7-OH), 11.03 (1H, s, 9-OH), 1.76 (3H, s, H-10), 2.66 (3H, s, H-12), 2.11 (3H, s,
H-13), 2.68 (3H, s, H-15); 13C-NMR (75 MHz in CDCl3) δ 198.0 (C-1), 105.1 (C-2), 191.69 (C-3), 98.27
(C-4), 179.29 (C-4a), 101.44 (C-6), 155.15 (C- 6a), 169.8 (C-7),109.3 (C-8), 157.42 (C-9), 103.88 (C-9a), 59.0
(C-9b), 32.0 (C-10), 201.7(C-11), 27.87 (C-12), 7.5 (C-13), 200.29 (C-14), 31.24 (C-15); ESI-MS m/z 343
[M − H]−.
3.5. Instrumental UPLC Conditions
High-resolution masses of secondary metabolites were measured after UPLC
separation. Chromatographic separation was performed on Acquity H Class UPLC system
(Waters, Milford, MA, USA) with a conditioned auto sampler, using an Acquity BEH C18 column
(100 × 2.1 mm id., 1.7 µm particle size) (Waters, Milford, MA, USA). Column temperature was
maintained at 40 ◦C. Mobile phase consisting of water with 0.1% formic acid in water (solvent
A) and acetonitrile with 0.1% formic acid (solvent B) was pumped at a flow rate of 0.4 mL/min.
Gradient elution program was as follows: 0 min, 5% B; 3.00 min, 20% B; 5.00 min, 35% B; 7.50 min,
50% B; 10.00 min, 70% B; 11.50 min, 85% B; 12.50 min 95% B; 17.00 min 95% B; 18.00 min 5% B.
Equilibration time was 2.8 min and injection volume was 1 µL. LC-QTOF-MSe mode was applied
to analyze the samples in both TIC as well as MS/MS mode where collision energy was ramped
at 15–45 eV. Eluted compounds were detected from m/z 50 to 1200 using Xevo G2-XS QTOF mass
spectrometer (Waters, Manchester, UK), which was connected to Electrospray ionization (ESI) interface
with negative ion mode using the following instrument settings, capillary voltage, 2.0 KV; sample
cone, 40 V; source temperature, 120 ◦C; desolvation temperature 350 ◦C; cone gas flow rate 50 L/h;
desolvation gas (N2) flow rate 850 L/h, Argon as CID gas for MS/MS experiments. All analyses were
performed using the lock spray, which ensured accuracy and reproducibility. Leucine-Enkephalin (5
ng/mL) was used as lock mass, generating a reference ion in negative mode at m/z 554.2615 introduced
by a lock spray at 10 µL/min for accurate mass acquisition. Data acquisition was achieved using Mass
lynx v 4.1 (Waters, Milford, MA, USA). Acquiring data in this manner provided information of intact
precursor ions as well as fragment ions.
3.6. Biological Activity
3.6.1. Cytotoxic Activity
MTT assay was performed as described earlier [28,37]. Cells were plated at a density of 1 × 104
cells/well in 100 µL Dulbecco’s Modified Eagle Medium (DMEM)/Minimum Essential Media (MEM)
medium, supplemented with 10% FBS in 96-well plates for 24 h. After incubation, cells were treated
with standard doxorubicin and test compounds for 48 h. After 48 h of treatment, 10 µL MTT
(3-(4,5-dimethylthiazol-2 yl)-2,5-diphenyl tetrazolium bromide) (5 mg/mL) were added to each well
and the plates were further incubated for 4 h. After 4 h, 100 µL DMSO was added to each well
and absorbance at 570 nm wavelength was recorded spectrophotometrically.
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3.6.2. Cell Cycle Analysis
Flow cytometric analysis (FACS) was performed to evaluate the cell cycle arrest. A549 cells
were seeded, incubated for 24 h and then treated with doxorubicin at 2 µM and compound 21 at 1
and 2 µM concentrations for 24 h. After that, cells were harvested and washed with phosphate
buffered saline (PBS) followed by fixation in ice cold 70% ethanol. After fixation cells were incubated
with RNase A (0.1 mg/mL) at 37 ◦C for 30 min and stained with propidium iodide (Sigma Aldrich,
St. Louis, MO, USA) (50 µg/mL) for 30 min on ice in dark. Cell cycle analysis was performed by flow
cytometry (Becton Dickinson FACS Caliber instrument) [32].
3.6.3. Hoechst Staining
A549 cells were seeded on cover slips and incubated for 24 h. After incubation, cells were
treated with doxorubicin at 2 µM and compound 21 at 1 and 2 µM concentrations for 48 h. After 48 h
treatment, Hoechst staining was performed using H33258 dye [38]. Florescence images were captured
by Olympus microscope using 10X lens.
3.6.4. Annexin V Assay for Apoptosis
A549 cells were seeded in six-well plates and incubated for 24 h. After incubation, cells were
treated with doxorubicin at 2 µM and compound 21 at 1 and 2 µM concentrations and further incubated
for 24 h. After 24 h treatment, cells were harvested by trypsinization. After harvesting, cells were
washed with PBS at 5000 rpm. After washing, cells were stained with Annexin-V and propidium iodide
using Annexin-V apoptosis detection kit (Sigma-Aldrich). Annexin V-FITC assay was performed
as described earlier [39].
3.6.5. Western Blotting Assay
Following treatments, cells were washed twice with PBS and lysed in 1× SDS sample buffer.
Proteins were separated on 10% SDS-polyacrylamide gels and transferred onto nitrocellulose
membranes. Membranes were washed twice with tween Tris-buffered saline before blocking nonspecific
binding with 5% nonfat dry milk (Blotto, Santa Cruz Biotechnology, Dallas, TX, USA) or 3% bovine
serum albumin. Anti-Poly ADP-ribose Polymerase (PARP) (11835238001-Roche) antibody, that detects
total and cleaved PARP was used at 1:1000 dilutions, and membranes were incubated for 2 h at room
temperature. Anti-Cyclin D1 (C7464, Sigma Aldrich) and anti-CDK4 (SAB140559, Sigma Aldrich) were
detected similar to PARP protein. Membranes were washed three times, and detection was performed
using horseradish peroxidase-conjugated secondary antibody as described previously [40].
3.6.6. Caspase-3 Assay
Following treatment, cell lysates were washed twice with phosphate-buffered saline and dissolved
in lysis buffer (50 mM HEPES (pH 7.4) containing 5 mM CHAPS and 5 mM DTT) for 15 min on ice.
Later, cells were centrifuged at 14,000× g for 15 min, under cold conditions, and collected the clear
supernatant. The supernatant was added to assay buffer (20 mM HEPES (pH 7.4), 2 mM EDTA, 0.1%
CHAPS, and 5 mM DTT) containing caspase 3 substrate (Ac-DEVD-AMC, 40 µM) in a final volume
of 100 µL as described earlier [41]. The incubation was performed for 1 h at 37 ◦C with readings
recorded at 5-min intervals. Fluorescence released by AMC was measured at 360-nm and 460-nm
excitation and emission wavelengths, respectively. Values were normalized to protein concentration
and expressed as fold change of activity relative to DMSO control [40].
3.6.7. Statistical Analysis
For cell cycle analysis and Annexin assays, one-way ANOVA followed by Tukey’s multiple
comparison tests was applied to compare the differences within the groups. Statistical analyses
were performed using GraphPad Prism version 5.01 (GraphPad Software Inc., San Diego, CA, USA).
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For caspase activity, statistical differences were calculated using Student’s t test and p values for pair
wise comparisons were calculated by employing a two-tailed t test. p < 0.05 was considered significant
for all the assays.
3.7. X-ray Crystal Data of 21
X-ray data was collected at room temperature using a Bruker Smart Apex CCD diffractometer with
graphite monochromated MoKα radiation (λ = 0.71073Å) withω-scan method [42]. Preliminary lattice
parameters and orientation matrices were obtained from four sets of frames. Integration and scaling
of intensity data were accomplished using the SAINT program. Structures were solved by direct
methods using SHELXS97 and refinement was carried out by full-matrix least-squares technique using
SHELXL97 [43]. Anisotropic displacement parameters were included for all non-hydrogen atoms.
The O bound H atoms were located in difference Fourier maps and their positions and isotropic
displacement parameters were refined. All other H atoms were positioned geometrically and treated
as riding on their parent C atoms, with C-H distances of 0.93–0.96 Å, and with Uiso(H) = 1.2Ueq (C)
or 1.5Ueq for methyl atoms [42].
Crystal Data for C19H20O7 (M = 360.37 g/mol): triclinic, space group P-1 (no. 2), a = 7.7896(16) Å,
b = 7.8083(16) Å, c = 14.169(3) Å, α = 90.052(3)◦, β = 99.293(3)◦, γ = 92.053(3)◦, V = 849.9(3) Å3,
Z = 2, T = 294.15 K, µ(Mo Kα) = 0.108 mm−1, Dcalc = 1.4080 g/cm3, 9792 reflections were measured
(2.92◦ ≤ 2Θ ≤ 56.82◦), 3961 unique (Rint = 0.0207, Rsigma = 0.0205), which were used in all calculations.
The final R1 was 0.0539 (I≥ 2u(I)) and wR2 was 0.1890 (all data). CCDC 1,831,752 contains supplementary
crystallographic data for the structure. These data can be obtained free of charge at www.ccdc.cam.
ac.uk/conts/retrieving.html (or from the Cambridge Crystallographic Data Centre (CCDC), 12 Union
Road, Cambridge CB2 1EZ, UK; fax: +44(0) 1223 336 033; email: deposit@ccdc.cam.ac.uk) [43].
4. Conclusion
As a support to studies reporting cytotoxicity of barbatic acid on cancer cell lines (HEp-2, NCI-H292
and KB) [44], our study confirmed that barbatic acid (21) has a marked activity (IC50 1.78 µM) against
the A549 cancer cell line and moderate activity (IC50 = 3.02–9.03 µM) on additional cancer cell lines
(HeLa, MCF-7 and DU-145) with some selectivity (IC50 = 124.9µM on HEK-293 embryonic cell line).
Various lines of evidence from our study support that barbatic acid (21) is a pro-apoptotic agent with
arrest in G0/G1 phase. Amongst them, annexin V and Hoechst staining demonstrated that barbatic
acid (21) causes cell death through nuclear damage and induces apoptosis by robust cleavage of PARP
protein. Further, a comprehensive analysis of acetone extract from U. longissima was carried out using
hyphenated UPLC-MS/MS for the first time which resulted in the identification and characterization
of 23 metabolites based on their accurate molecular masses and molecular formula. Among them,
compounds 1 and 6 were identified by MS/MS by comparison with standards and compounds 19–22
were identified by MS/MS by comparison with isolated compounds. Nine compounds including five
lipids, two paraconic acids, and two usnic acid derivatives were putatively identified for the first time
by MS/MS, and fragmentation patterns supporting their structures were proposed. Such a chemical
study is mandatory when chemotypes are concerned and could explain some differences in efficacy
or uses of traditional herbal medicines. In this case, barbatic acid is abundant in the U. longissima
chemotype studied but this common lichen species can have great variations in its chemical profile.
Finally, our findings strongly suggest that barbatic acid (21) is a real cytotoxic agent against A549
cells and can be considered as a new drug candidate to be assessed on oncogene-specific aggressive
lung cancers.
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